IL-7 and Flt-3L plasma levels are increased during highly active antiretroviral therapy-associated IL-2 therapy.
IL-2 is used in conjunction with highly active antiretroviral therapy to increase the CD4 cell count in HIV-positive patients. The mechanisms involved remain ill-defined. Here we show that during the first cycle of IL-2 therapy, IL-7 and Flt-3L plasma levels are increased, whereas levels of stem cell factor are unchanged. This supports the hypothesis that aside from stimulating CD4 T cells IL-2 may also indirectly affect lymphocyte production through the stimulation of lymphopoietic cytokines.
Beq
Stéphanie
S
Unité d'ImmunoGénétique Cellulaire, Institut Pasteur, Paris, France.
Fontanet
Arnaud
A
Theze
Jacques
J
Colle
Jean-Hervé
JH
D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D007376:Interleukin-2 / Q000627:therapeutic use*; D015851:Interleukin-7 / Q000378:metabolism*; D008231:Lymphopenia / Q000188:drug therapy; D011518:Proto-Oncogene Proteins / Q000378:metabolism*; D020794:Receptor Protein-Tyrosine Kinases / Q000378:metabolism*; D012189:Retrospective Studies; D019089:Stem Cell Factor / Q000378:metabolism; D051941:fms-Like Tyrosine Kinase 3
D007376:Interleukin-2; D015851:Interleukin-7; D011518:Proto-Oncogene Proteins; D019089:Stem Cell Factor; C497970:FLT3 protein, human; D020794:Receptor Protein-Tyrosine Kinases; D051941:fms-Like Tyrosine Kinase 3